US EditionTrump administration announces 15 new drugs for Medicare price negotiation program
The third Medicare negotiation round includes 15 drugs covering diabetes, HIV, and arthritis, with savings targeting $27 billion in spending, CMS said.
- On Tuesday, the Trump administration announced the next 15 drugs for Medicare price negotiations, marking the first year Medicare Part B medicines are eligible as the government met its Feb. 1 deadline.
- The negotiations stem from the Inflation Reduction Act of 2022, which gave CMS authority to select high‑spend drugs based on statutory criteria, including being 7 or 11 years post‑FDA approval and lacking generics, for about $27 billion in Medicare Part B and Part D spending in the past year.
- Notable entries range from diabetes medicines to cancer therapies and include Trulicity , Biktarvy , Botox and Xeljanz , covering diabetes, HIV, arthritis, cancer and autoimmune diseases.
- Companies have until Feb. 28 to decide on participation, CMS said Tradjenta will undergo renegotiation, and shares of Gilead, Eli Lilly, AbbVie, Johnson & Johnson, Pfizer and Bristol Myers rose nearly 2%.
- Cumulatively the program could yield significant taxpayer relief as this third round brings 40 drugs total and follows 36% savings on 15 drugs starting in 2027, about $8.5 billion.
97 Articles
97 Articles
With CMS’s New List of Meds for Drug Price Negotiation, Analyst Sees Small Financial Hit to Pharmas
The 15 drugs selected for the Centers for Medicare and Medicaid Services drug price negotiation program accounted for about $27 billion in total prescription spending under Medicare Parts B and D. But this revenue from Medicare makes up a small percentage of each drug manufacturer’s total sales. The post With CMS’s New List of Meds for Drug Price Negotiation, Analyst Sees Small Financial Hit to Pharmas appeared first on MedCity News.
Botox, 14 Other Drugs to Be Negotiated by Medicare This Year
Botox and Trulicity are two well-known medications that will be included in the next round of Medicare price negotiations scheduled for this year. It will be the third round of price negotiations between Medicare and pharmaceutical manufacturers. The Inflation Reduction Act of 2022 authorized the Medicare program to negotiate with drug makers for the first time. Medicare, the world’s largest buyer of prescription drugs, must negotiate prices for…
MedPage Today
Anti-Aging, Acupuncture and Health NewsBotox, Trulicity, and 13 Other Drugs Selected for Medicare Price Negotiation
(MedPage Today) -- The popular type 2 diabetes drug dulaglutide (Trulicity), botulinum toxin (Botox), and drugs to treat psoriatic arthritis, prostate cancer, and breast cancer are among the 15 drugs that the Centers for Medicare & Medicaid...
Coverage Details
Bias Distribution
- 77% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
